We are live on ! Find out more
CTKB icon

Cytek Biosciences
CTKB

52 hedge funds and large institutions have $572M invested in Cytek Biosciences in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 9 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

122% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 9

0.51% more ownership

Funds ownership: 25.69% → 26.2% (+0.51%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less funds holding

Funds holding: 54 → 52 (-2)

15% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 13

23% less capital invested

Capital invested by funds: $744M → $572M (-$172M)

Holders
52
Holders Change
-2
Holders Change %
-3.7%
% of All Funds
0.8%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
11
Increased
20
Reduced
9
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MGM
Miura Global Management
New York
+$18.9M
2
BlackRock
BlackRock
New York
+$10.8M
3
E
Ergoteles
New York
+$3.71M
4
Renaissance Technologies
Renaissance Technologies
New York
+$2.28M
5
PPA
Parametric Portfolio Associates
Washington
+$1.63M

Top Sellers

Rank Fund Capital Flow
1
RFA
Reilly Financial Advisors
California
-$10.6M
2
DCM
Driehaus Capital Management
Illinois
-$9.45M
3
SAM
Sectoral Asset Management
Quebec, Canada
-$7.02M
4
Millennium Management
Millennium Management
New York
-$3.83M
5
CCM
CAAS Capital Management
New York
-$2.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
Manulife (Manufacturers Life Insurance)
51
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$170 +$218K +10,392 New
DCM
52
Driehaus Capital Management
Illinois
– -$9.45M -441,518 Closed
SAM
53
Sectoral Asset Management
Quebec, Canada
– -$7.02M -328,080 Closed
Millennium Management
54
Millennium Management
New York
– -$3.83M -178,978 Closed
CCM
55
CAAS Capital Management
New York
– -$2.14M -100,000 Closed
Ameriprise
56
Ameriprise
Minnesota
– -$1.88M -87,634 Closed
RFA
57
Reilly Financial Advisors
California
– -$10.6M -79,979 Closed
Alyeska Investment Group
58
Alyeska Investment Group
Illinois
– -$1.61M -75,000 Closed
GCM
59
Ghisallo Capital Management
Massachusetts
– -$1.07M -50,000 Closed
CSS
60
Cubist Systematic Strategies
Connecticut
– -$184K -8,600 Closed
SG Americas Securities
61
SG Americas Securities
New York
– -$148K -6,890 Closed
UBS Group
62
UBS Group
Switzerland
– -$18K -831 Closed
PHK
63
Point72 Hong Kong
Hong Kong
– -$16K -749 Closed
US Bancorp
64
US Bancorp
Minnesota
– -$7K -320 Closed
1 2
3

CTKB Hedge Fund Activity: Q4 2021 in Review

52 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q4 2021, worth a combined $572M — down 23% from $744M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CTKB and 11 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 20 added.

The largest buyer was Miura Global Management, adding an estimated $18.9M. The largest seller was Reilly Financial Advisors, exiting entirely with an estimated $10.6M sold.

  • 52 institutional investors held Cytek Biosciences (CTKB) as of Q4 2021, down from 54 in Q3 2021.
  • Funds reported $572M of Cytek Biosciences stock for Q4 2021, down 23% quarter-over-quarter.
  • 11 funds opened new Cytek Biosciences positions in Q4 2021 and 13 closed out, a net change of -2 holders.
  • The largest Cytek Biosciences buyer in Q4 2021 was Miura Global Management, an estimated $18.9M added.
  • The largest Cytek Biosciences seller in Q4 2021 was Reilly Financial Advisors, an estimated $10.6M sold.

Based on aggregated 13F filings for Q4 2021.